{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:14:46Z","timestamp":1793211286695,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Advances in immunosuppressive therapy have markedly improved short-term graft survival post-kidney transplantation (KT); however, these advances have also profoundly altered long-term disease patterns in transplant recipients. Cancer remains a major barrier limiting improvements in long-term survival. Kidney transplant recipients are at increased risk of malignancy owing to impaired graft function and immunosuppressive medications. To improve cancer-related outcomes, comprehensive strategies encompassing prevention, early detection through screening, and appropriate treatment are required. Primary prevention includes the appropriate selection and maintenance of immunosuppressive medications, careful consideration of KT indications for recipients and donors with previously treated cancers, and vaccination. Secondary prevention requires effective, risk-adapted cancer screening in high-risk kidney transplant recipients. Following a cancer diagnosis, management includes localized resection and systemic therapy for primary, recurrent, or refractory disease. Systemic therapy includes chemotherapy and immunotherapy, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, which may affect graft function and cause treatment-specific adverse effects. Additionally, immunosuppressive medications often require modification to minimize the risk of graft rejection while maintaining a low likelihood of recurrence. In this review, we summarize current strategies for cancer prevention, screening, and treatment following KT.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1784083","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:32:00Z","timestamp":1774416720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical management of cancer after kidney transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Takahisa","family":"Hiramitsu","sequence":"first","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Ienaga","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shimamoto","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Himeno","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Narumi","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Watarai","sequence":"additional","affiliation":[{"name":"Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital","place":["Nagoya, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06100617","article-title":"Association of kidney transplantation with survival in patients with long dialysis exposure","volume":"12","author":"Rose","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e047263","DOI":"10.1136\/bmjopen-2020-047263","article-title":"Changes in quality of life (QoL) and other patient-reported outcome measures (PROMs) in living-donor and deceased-donor kidney transplant recipients and those awaiting transplantation in the UK ATTOM programme: a longitudinal cohort questionnaire survey with additional qualitative interviews","volume":"11","author":"Gibbons","year":"2021","journal-title":"BMJ Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03208-2","article-title":"Dialysis or kidney transplantation in older adults? A systematic review summarizing functional, psychological, and quality of life-related outcomes after start of kidney replacement therapy","volume":"54","author":"Schoot","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e29591","DOI":"10.1371\/journal.pone.0029591","article-title":"Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities","volume":"7","author":"Wong","year":"2012","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00700117","article-title":"Donor-specific antibodies in kidney transplant recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107038","article-title":"Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: a retrospective cohort study","volume":"91","author":"Hiramitsu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030287","article-title":"Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"Samaniego","year":"2016","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13734","article-title":"Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study","volume":"33","author":"Benoni","year":"2020","journal-title":"Transpl Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14570920","article-title":"De novo Malignancies after kidney transplantation","volume":"17","author":"Al-Adra","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1273","DOI":"10.1097\/TXD.0000000000001273","article-title":"Death with function and graft failure after kidney transplantation: risk factors at baseline suggest new approaches to management","volume":"8","author":"Merzkani","year":"2022","journal-title":"Transplant Direct"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32585","article-title":"Cancer mortality in kidney transplant recipients: an Australian and New Zealand population-based cohort study, 1980\u20132013","volume":"146","author":"Rosales","year":"2020","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.8.1672","article-title":"Patient survival after renal transplantation; more than 25 years follow-up","volume":"12","author":"Arend","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.458","article-title":"Malignancy-related mortality following kidney transplantation is common","volume":"85","author":"Farrugia","year":"2014","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ff1458","article-title":"Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study","volume":"90","author":"van de Wetering","year":"2010","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0242805","DOI":"10.1371\/journal.pone.0242805","article-title":"De-novo Malignancies after kidney transplantation: A long-term observational study","volume":"15","author":"Fr\u00f6hlich","year":"2020","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20781","article-title":"Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer \u2013 a population cohort study","volume":"8","author":"Lim","year":"2017","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004493","article-title":"Variations in risk of cancer and death from cancer according to kidney allograft function, graft loss, and return to dialysis","volume":"107","author":"Au","year":"2023","journal-title":"Transplantation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.02.028","article-title":"The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatch","volume":"24","author":"Attieh","year":"2024","journal-title":"Am J Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1042","article-title":"Thymoglobulin versus alemtuzumab versus basiliximab kidney transplantation from donors after circulatory death","volume":"7","author":"Asderakis","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005632.pub3","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients","volume":"2016","author":"Haller","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34875","article-title":"Immunosuppression and cancer risk in kidney transplant recipients: a retrospective cohort study","volume":"154","author":"Sapir-Pichhadze","year":"2024","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of Malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1678309","article-title":"Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant","volume":"16","author":"Hiramitsu","year":"2026","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.238","article-title":"Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients","volume":"37","author":"Okamoto","year":"2005","journal-title":"Transplant Proc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002762","article-title":"Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention","volume":"103","author":"Metz","year":"2019","journal-title":"Transplantation"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000113248.59077.76","article-title":"Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal","volume":"15","author":"Kreis","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower Malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"Alber\u00fa","year":"2011","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on Malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/srep21312","article-title":"Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: a nationwide population-based cohort study","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.11.021","article-title":"Renal transplantation in patients with human T-cell lymphotropic virus type 1","volume":"44","author":"Shirai","year":"2012","journal-title":"Transplant Proc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e13314","DOI":"10.1111\/tid.13314","article-title":"Long-term prognosis in kidney transplant recipients with human T-cell leukemia virus type 1 infection","volume":"22","author":"Goto","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e52527","DOI":"10.7759\/cureus.52527","article-title":"Evaluating Kaposi sarcoma in kidney transplant patients: a systematic review and meta-analysis","volume":"16","author":"Saowapa","year":"2024","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e14763","DOI":"10.1111\/petr.14763","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: a prospective multicenter study in the United States","volume":"28","author":"Tajima","year":"2024","journal-title":"Pediatr Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1057454","article-title":"Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence","volume":"10","author":"Nailescu","year":"2022","journal-title":"Front Pediatr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nep.13741","article-title":"Vaccination in patients with chronic kidney disease-review of current recommendations and recent advances","volume":"26","author":"Ma","year":"2021","journal-title":"Nephrol (Carlton)"},{"key":"B49","article-title":"Evaluation of the candidate with a previous Malignancy","volume":"2","author":"Penn","year":"1996","journal-title":"Liver Transpl Surg"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002178","article-title":"Solid organ transplantation in patients with preexisting Malignancies in remission: a propensity score matched cohort study","volume":"102","author":"Acuna","year":"2018","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/TP.0b013e31829854b7","article-title":"Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history","volume":"96","author":"Brattstr\u00f6m","year":"2013","journal-title":"Transplantation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2019.06.001","article-title":"Impact of pre-transplant Malignancy on outcomes after kidney transplantation: United Network for Organ Sharing Database Analysis","volume":"229","author":"Livingston-Rosanoff","year":"2019","journal-title":"J Am Coll Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13593","article-title":"Recommendations for solid organ transplantation for transplant candidates with a pretransplant diagnosis of cutaneous squamous cell carcinoma, Merkel cell carcinoma and melanoma: a consensus opinion from the International Transplant Skin Cancer Collaborative (ITSCC)","volume":"16","author":"Zwald","year":"2016","journal-title":"Am J Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ Malignancy and organ transplant candidacy: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological Malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000545","article-title":"Cancer screening and cancer treatment in kidney transplant recipients","volume":"5","author":"Bigotte Vieira","year":"2024","journal-title":"Kidney360"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.69408\/jscrt.13.2_100","article-title":"Cancer after kidney transplantation","volume":"13","author":"Hiramitsu","year":"2025","journal-title":"J Jpn Soc Clin Ren Transpl"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"B59","unstructured":"Annual activity report. Section 5 Kidney Activity\n          \n          2025"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04160511","article-title":"Living kidney donors ages 70 and older: recipient and donor outcomes","volume":"6","author":"Berger","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318272df41","article-title":"Cancer transmission from organ donors-unavoidable but low risk","volume":"94","author":"Desai","year":"2012","journal-title":"Transplantation"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-00573-z","article-title":"How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network","volume":"32","author":"Eccher","year":"2019","journal-title":"J Nephrol"},{"key":"B63","unstructured":"London\n          Department of Health and Social Care. Advisory Committee on the Safety of Blood, Tissues and Organs\n          Transplantation of organs from deceased donors with cancer or a history of cancer\n          \n          2020"},{"key":"B64","unstructured":"Strasbourg\n          Council of Europe\n          Care (EDQM), Council of Europe. Guide to the quality and safety of organs for transplantation\n          \n          2022"},{"key":"B65","unstructured":"Sydney\n          TSANZ\n          TSANZ clinical guidelines for organ transplantation\n          \n          2023"},{"key":"B66","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/TP.0000000000001769","article-title":"KDIGO clinical practice guideline on the evaluation and care of living kidney donors","volume":"101","author":"Lentine","year":"2017","journal-title":"Transplantation"},{"key":"B67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-319-56017-5_3","article-title":"UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer","volume":"996","author":"Liu-Smith","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14382","article-title":"Skin cancers in organ transplant recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1848068","article-title":"Cancer risks in solid organ transplant recipients: results from a comprehensive analysis of 72 cohort studies","volume":"9","author":"Huo","year":"2020","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05740.x","article-title":"A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients","volume":"149","author":"Fuente","year":"2003","journal-title":"Br J Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12882-022-02997-z","article-title":"An integrated skin cancer education program in renal transplant recipients and patients with glomerular disease","volume":"23","author":"Thet","year":"2022","journal-title":"BMC Nephrol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14694\/EdBook_AM.2015.35.57","article-title":"Early detection of cancer: past, present, and future","author":"Schiffman","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B73","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.2215\/CJN.03320807","article-title":"Cancer screening in renal transplant recipients: what is the evidence","volume":"3","author":"Wong","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13978","article-title":"Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transplant"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2021.100625","article-title":"Sex differences in cancer risk and outcomes after kidney transplantation","volume":"35","author":"Buxeda","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1681\/ASN.V11suppl_1s1","article-title":"Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.05.004","article-title":"Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"56","author":"Knoll","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2011.01559.x","article-title":"KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"17","author":"Chadban","year":"2012","journal-title":"Nephrol (Carlton)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_4.3","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1159\/000328074","article-title":"Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient","volume":"118","author":"Baker","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e0158732","DOI":"10.1371\/journal.pone.0158732","article-title":"Independent pre-transplant recipient cancer risk factors after kidney transplantation and the utility of G-chart analysis for clinical process control","volume":"11","author":"Schrem","year":"2016","journal-title":"PloS One"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac337","article-title":"Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis","volume":"38","author":"Massicotte-Azarniouch","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001280","article-title":"Late persistent positive EBV viral load and risk of solid cancer in kidney transplant patients","volume":"101","author":"Bamoulid","year":"2017","journal-title":"Transplantation"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3636","article-title":"Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study","volume":"10","author":"Imamura","year":"2021","journal-title":"Cancer Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2010.01070.x","article-title":"Autosomal dominant polycystic kidney disease: risk factor for nonmelanoma skin cancer following kidney transplantation","volume":"23","author":"Bretagnol","year":"2010","journal-title":"Transpl Int"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-137","article-title":"Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis \u2013 an observational cohort study","volume":"14","author":"Skov Dalgaard","year":"2013","journal-title":"BMC Nephrol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14530","article-title":"Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000760","article-title":"Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer","volume":"99","author":"Viecelli","year":"2015","journal-title":"Transplantation"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10700-7","article-title":"Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis","volume":"18","author":"Lv","year":"2024","journal-title":"Hepatol Int"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13806","article-title":"Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis","volume":"52","author":"Tahata","year":"2022","journal-title":"Hepatol Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14225","article-title":"The risk of developing hepatocellular carcinoma persists in chronic hepatitis B patients even after the long-term administration of nucleos(t)ide analogs","volume":"55","author":"Murai","year":"2025","journal-title":"Hepatol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918331","article-title":"Effectiveness and safety of therapeutic vaccines for precancerous cervical lesions: a systematic review and meta-analysis","volume":"12","author":"Cai","year":"2022","journal-title":"Front Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6255339","article-title":"Mammalian target of rapamycin inhibitors and wound healing complications in kidney transplantation: old myths and new realities","volume":"2022","author":"Mabood Khalil","year":"2022","journal-title":"J Transplant"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/tri.14115","article-title":"Chemotherapy, targeted therapy and immunotherapy: which drugs can be safely used in the solid organ transplant recipients","volume":"34","author":"Maggiore","year":"2021","journal-title":"Transpl Int"},{"key":"B96","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21636","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2008.00893.x","article-title":"Management of leukopenia in kidney and pancreas transplant recipients","volume":"22","author":"Hartmann","year":"2008","journal-title":"Clin Transplant"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2015.00018","article-title":"Blood disorders typically associated with renal transplantation","volume":"3","author":"Yang","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1086\/383053","article-title":"The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments","volume":"39","author":"Rolston","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13204","article-title":"Immunotherapy for cancer in kidney transplant patients: a difficult balance between risks and benefits","volume":"37","author":"Bolufer","year":"2024","journal-title":"Transpl Int"},{"key":"B107","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13952","article-title":"for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project. Managing immunosuppressive therapy in potentially cured post-kidney transplant cancer (excluding non-melanoma skin cancer: an overview of the available evidence and guidance for shared decision-making","volume":"34","author":"Hellemans","year":"2021","journal-title":"Transpl Int"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transplant"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results","volume":"36","author":"Dantal","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:32:22Z","timestamp":1774416742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2026.1784083"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1784083","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"1784083"}}